Chiasma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 85
- Market Cap
- -
- Website
- https://chiasma.com
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03252353
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT02685709
- Locations
- 🇵🇱
Katedra i Klinika Endokrynologii i Chorob Wewnetrznych Gdanski Uniwersytet Medyczny, Gdańsk, Poland
🇺🇸Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01412424
- Locations
- 🇭🇺
Military Hospital, State Health Center 2nd Department of Internal Medicine, Budapest, Hungary
🇲🇽Instituto Nacional de Neurologia y Neurocirugía - National Institute of Neurology and Neurosurgery, Mexico City, Mexico
🇭🇺University of Pecs, Pecs, Hungary
© Copyright 2025. All Rights Reserved by MedPath